biomarkers, tumor

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
Julie Lecuelle, Laure Favier, Cléa Fraisse, Aurélie Lagrange, Coureche Kaderbhai, Romain Boidot, Sandy Chevrier, Philippe Joubert, Bertrand Routy, Caroline Truntzer, Francois Ghiringhelli

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004241; DOI: 10.1136/jitc-2021-004241
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Siwen Hu-Lieskovan, Srabani Bhaumik, Kavita Dhodapkar, Jean-Charles J B Grivel, Sumati Gupta, Brent A Hanks, Sylvia Janetzki, Thomas O Kleen, Yoshinobu Koguchi, Amanda W Lund, Cristina Maccalli, Yolanda D Mahnke, Ruslan D Novosiadly, Senthamil R Selvan, Tasha Sims, Yingdong Zhao, Holden T Maecker

Journal for ImmunoTherapy of Cancer Dec 2020, 8 (2) e000705; DOI: 10.1136/jitc-2020-000705
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
Alissa Keegan, Biagio Ricciuti, Padric Garden, Limor Cohen, Reiko Nishihara, Anika Adeni, Cloud Paweletz, Julianna Supplee, Pasi A Jänne, Mariano Severgnini, Mark M Awad, David R Walt

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000678; DOI: 10.1136/jitc-2020-000678
Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
Florian Camy, Georgia Karpathiou, Jean Marc Dumollard, Nicolas Magne, Jean Luc Perrot, Francois Vassal, Tiphanie Picot, Mousa Mobarki, Fabien Forest, Francois Casteillo, Sirine Hathroubi, Marios Froudarakis, Michel Peoc'h

Journal for ImmunoTherapy of Cancer Aug 2020, 8 (2) e000597; DOI: 10.1136/jitc-2020-000597
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, Ben Wang, Shu Yi Shen, Ilias Ettayebi, Charles A Ishak, Philippe L Bedard, Albiruni Abdul Razak, Aaron R Hansen, Anna Spreafico, Dave Cescon, Marcus O Butler, Amit M Oza, Stephanie Lheureux, Neda Stjepanovic, Brendan Van As, Sarah Boross-Harmer, Lisa Wang, Trevor J Pugh, Pamela S Ohashi, Lillian L Siu, Daniel D De Carvalho

Journal for ImmunoTherapy of Cancer Aug 2020, 8 (2) e000883; DOI: 10.1136/jitc-2020-000883
Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
Arissa C Young, Henry T Quach, Haocan Song, Elizabeth J Davis, Javid J Moslehi, Fei Ye, Grant R Williams, Douglas B Johnson

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000821; DOI: 10.1136/jitc-2020-000821
Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
David Chardin, Marie Paquet, Renaud Schiappa, Jacques Darcourt, Caroline Bailleux, Michel Poudenx, Aurélie Sciazza, Marius Ilie, Jonathan Benzaquen, Nicolas Martin, Josiane Otto, Olivier Humbert

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000645; DOI: 10.1136/jitc-2020-000645
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
Bingxi He, Di Dong, Yunlang She, Caicun Zhou, Mengjie Fang, Yongbei Zhu, Henghui Zhang, Zhipei Huang, Tao Jiang, Jie Tian, Chang Chen

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000550; DOI: 10.1136/jitc-2020-000550
Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma
Fangming Liu, Weiren Liu, Shuang Zhou, Chunhui Yang, Mengxin Tian, Guangshuai Jia, Han Wang, Bijun Zhu, Mingxiang Feng, Yan Lu, Tiankui Qiao, Xinxin Wang, Wei Cao, Xiangdong Wang, Yinghong Shi, Duojiao Wu

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000501; DOI: 10.1136/jitc-2019-000501
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Xue Bai, De-Hua Wu, Si-Cong Ma, Jian Wang, Xin-Ran Tang, Shuai Kang, Qiang John Fu, Chuan-Hui Cao, He-San Luo, Yu-Han Chen, Hong-Bo Zhu, Hong-Hong Yan, Yi-Long Wu, Zhong-Yi Dong

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000381; DOI: 10.1136/jitc-2019-000381

Main menu

biomarkers, tumor

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

biomarkers, tumor

Pages